Maxime P Look

Summary

Affiliation: University Hospital Rotterdam
Country: The Netherlands

Publications

  1. ncbi Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients
    Maxime P Look
    Department of Medical Oncology, University Hospital Rotterdam, The Netherlands
    J Natl Cancer Inst 94:116-28. 2002
  2. ncbi HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study
    Maurice P H M Jansen
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 25:662-8. 2007
  3. doi Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer
    Maurice P H M Jansen
    Department of Medical Oncology, Erasmus MC, Josephine Nefkens Institute, Rotterdam, The Netherlands
    Breast Cancer Res Treat 116:263-71. 2009
  4. doi MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer
    F Germán Rodríguez-González
    Department of Medical Oncology, Erasmus Medical Center Rotterdam, Josephine Nefkens Institute and Cancer Genomics Centre, Dr Molewaterplein 50, Be 4 02 lab 4 35b office, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Breast Cancer Res Treat 127:43-51. 2011
  5. ncbi Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease
    Marion E Meijer-Van Gelder
    Department of Medical Oncology, Erasmus MC Rotterdam, Rotterdam, The Netherlands
    Cancer Res 64:4563-8. 2004
  6. doi Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response
    Jozien Helleman
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Clin Cancer Res 14:5555-64. 2008
  7. pmc Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer
    John A Foekens
    Department of Medical Oncology, Erasmus Medical Center Rotterdam, Josephine Nefkens Institute, 3000 CA Rotterdam, The Netherlands
    Proc Natl Acad Sci U S A 105:13021-6. 2008
  8. doi Correlation of breast cancer susceptibility loci with patient characteristics, metastasis-free survival, and mRNA expression of the nearest genes
    Muhammad Riaz
    Department of Medical Oncology, Josephine Nefkens Institute and Daniel den Hoed Cancer Center, Erasmus MC, Building Be, Room 400, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands
    Breast Cancer Res Treat 133:843-51. 2012
  9. ncbi Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer
    John W M Martens
    Department of Medical Oncology, Erasmus MC, Rotterdam, The Netherlands
    Cancer Res 65:4101-17. 2005
  10. ncbi Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients
    Anieta M Sieuwerts
    Department of Medical Oncology, Erasmus MC, Rotterdam, The Netherlands
    Clin Cancer Res 12:3319-28. 2006

Collaborators

Detail Information

Publications27

  1. ncbi Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients
    Maxime P Look
    Department of Medical Oncology, University Hospital Rotterdam, The Netherlands
    J Natl Cancer Inst 94:116-28. 2002
    ....
  2. ncbi HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study
    Maurice P H M Jansen
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 25:662-8. 2007
    ..However, this ratio may predict a tumor's response to tamoxifen, its intrinsic aggressiveness, or both...
  3. doi Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer
    Maurice P H M Jansen
    Department of Medical Oncology, Erasmus MC, Josephine Nefkens Institute, Rotterdam, The Netherlands
    Breast Cancer Res Treat 116:263-71. 2009
    ..The aim of this study was to evaluate SIAH2 for its (a) predictive/prognostic value, and (b) functional role in endocrine therapy resistance...
  4. doi MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer
    F Germán Rodríguez-González
    Department of Medical Oncology, Erasmus Medical Center Rotterdam, Josephine Nefkens Institute and Cancer Genomics Centre, Dr Molewaterplein 50, Be 4 02 lab 4 35b office, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Breast Cancer Res Treat 127:43-51. 2011
    ..Assessment of tumor levels and connected pathways could be helpful to improve treatment strategies...
  5. ncbi Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease
    Marion E Meijer-Van Gelder
    Department of Medical Oncology, Erasmus MC Rotterdam, Rotterdam, The Netherlands
    Cancer Res 64:4563-8. 2004
    ..Knowledge of their tumor expression levels might be helpful for future individualized therapy protocols, including possible new-targeted therapies based on the interference in the urokinase system...
  6. doi Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response
    Jozien Helleman
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Clin Cancer Res 14:5555-64. 2008
    ....
  7. pmc Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer
    John A Foekens
    Department of Medical Oncology, Erasmus Medical Center Rotterdam, Josephine Nefkens Institute, 3000 CA Rotterdam, The Netherlands
    Proc Natl Acad Sci U S A 105:13021-6. 2008
    ..In conclusion, our work connects four miRNAs to breast cancer progression and to several distinct biological processes involved therein...
  8. doi Correlation of breast cancer susceptibility loci with patient characteristics, metastasis-free survival, and mRNA expression of the nearest genes
    Muhammad Riaz
    Department of Medical Oncology, Josephine Nefkens Institute and Daniel den Hoed Cancer Center, Erasmus MC, Building Be, Room 400, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands
    Breast Cancer Res Treat 133:843-51. 2012
    ..Also the prognosis of patients is largely not affected by low-risk breast cancer loci except for the SNP near H19. How, this SNP affects prognosis warrants further study as it does not operate through altering H19 mRNA expression...
  9. ncbi Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer
    John W M Martens
    Department of Medical Oncology, Erasmus MC, Rotterdam, The Netherlands
    Cancer Res 65:4101-17. 2005
    ..Concluding, our work indicates that promoter hypermethylation and mRNA expression of PSAT1 are indicators of response to tamoxifen-based endocrine therapy in steroid hormone receptor-positive patients with recurrent breast cancer...
  10. ncbi Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients
    Anieta M Sieuwerts
    Department of Medical Oncology, Erasmus MC, Rotterdam, The Netherlands
    Clin Cancer Res 12:3319-28. 2006
    ..To evaluate the prognostic value of cyclin E with a quantitative method for lymph node-negative primary breast cancer patients...
  11. pmc Clinical significance of the nuclear receptor co-regulator DC-SCRIPT in breast cancer: an independent retrospective validation study
    Anieta M Sieuwerts
    Department of Medical Oncology, Josephine Nefkens Institute and Cancer Genomics Centre, Erasmus Medical Center, Rotterdam, GE, The Netherlands
    Breast Cancer Res 12:R103. 2010
    ....
  12. ncbi Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling
    Maurice P H M Jansen
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 23:732-40. 2005
    ..To discover a set of markers predictive for the type of response to endocrine therapy with the antiestrogen tamoxifen using gene expression profiling...
  13. ncbi Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer
    Els M J J Berns
    Department of Medical Oncology, Erasmus MC Daniel den Hoed, 3000 DR Rotterdam, The Netherlands
    Clin Cancer Res 9:1253-8. 2003
    ..Mutant TP53 may up-regulate VEGF, whereas, on the other hand, wild-type TP53 may decrease VEGF production...
  14. doi Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen
    Diana E Ramirez-Ardila
    Department of Medical Oncology, Erasmus MC Cancer Institute, Room Be424, PO Box 2040, 3000 CA, Rotterdam, The Netherlands
    Breast Cancer Res Treat 139:39-49. 2013
    ..Mutations were not associated with prognosis in untreated LNN patients nor predictive outcome after first-line tamoxifen therapy in advanced disease patients...
  15. ncbi RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response
    Herman Burger
    Department of Medical Oncology, Erasmus Medical Center Rotterdam Daniel den Hoed Kliniek Josephine Nefkens Institute, 3000 DR Rotterdam, The Netherlands
    Clin Cancer Res 9:827-36. 2003
    ..The aim of this study was to investigate whether expression of particular drug resistance genes in primary operable breast cancer correlates with response to first-line chemotherapy in advanced disease...
  16. ncbi The prognostic value of polymorphonuclear leukocyte elastase in patients with primary breast cancer
    John A Foekens
    Erasmus MC Daniel den Hoed, Department of Medical Oncology, 3000 DR Rotterdam, The Netherlands
    Cancer Res 63:337-41. 2003
    ..Our present study suggests that PMN-E is associated with breast cancer metastasis, and knowledge of the tumor PMN-E status might be helpful in selecting the appropriate individualized (adjuvant) treatment for patients with breast cancer...
  17. ncbi Prognostic value of plasminogen activator inhibitor-1 in head and neck squamous cell carcinoma
    Lucienne Speleman
    Department of Otolaryngology Head and Neck Surgery, Erasmus MC Daniel den Hoed, Rotterdam, The Netherlands
    Head Neck 29:341-50. 2007
    ..In this study, the prognostic importance of these factors in patients with primary head and neck squamous cell carcinoma (HNSCC) was evaluated and correlated with clinicopathologic variables...
  18. ncbi Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424)
    Nadia Harbeck
    Department of Obstetrics and Gynecology, Technical University, D 81675 Munich, Germany
    Cancer Res 62:4617-22. 2002
    ....
  19. ncbi The prognostic value of BCAR1 in patients with primary breast cancer
    Lambert C J Dorssers
    Department of Pathology, Division of Molecular Biology, Erasmus MC Rotterdam, Rotterdam
    Clin Cancer Res 10:6194-202. 2004
    ..Here, we study the prognostic value of quantitative BCAR1 levels in a large series of breast cancer specimens...
  20. ncbi Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer
    Nadia Harbeck
    Department of Obstetrics and Gynecology, Technical University of Munich, Germany
    Clin Breast Cancer 5:348-52. 2004
    ....
  21. ncbi Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer
    Danielle Meijer
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    Endocr Relat Cancer 15:101-11. 2008
    ..In addition, as altered expression of FGF17 causes tamoxifen resistance in vitro, the FGF signaling pathway could be a valuable target in the treatment of breast cancer patients resistant to endocrine treatment...
  22. ncbi DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients
    Inko Nimmrich
    Department of Biomedical Research and Development and Technology Development, Epigenomics AG, Berlin, Germany
    Breast Cancer Res Treat 111:429-37. 2008
    ..In addition, we studied the association between PITX2 DNA methylation and PITX2 gene expression...
  23. pmc GnRH and LHR gene variants predict adverse outcome in premenopausal breast cancer patients
    Djura Piersma
    Department of Internal Medicine, Erasmus MC, 3000 CA Rotterdam, The Netherlands
    Breast Cancer Res 9:R51. 2007
    ..Breast cancer development and progression are dependent on estrogen activity. In premenopausal women, estrogen production is mainly regulated through the hypothalamic-pituitary-gonadal (HPG) axis...
  24. ncbi Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer
    Anne Sofie Schrohl
    Department of Veterinary Pathobiology, The Royal Veterinary and Agricultural University, Frederiksberg C, Denmark
    Clin Cancer Res 12:7054-8. 2006
    ....
  25. ncbi Application of a newly developed ELISA for BCAR1 protein for prediction of clinical benefit of tamoxifen therapy in patients with advanced breast cancer
    Lambert C J Dorssers
    Department of Pathology, Division of Molecular Biology, Erasmus MC Rotterdam, Rotterdam, The Netherlands
    Clin Chem 50:1445-7. 2004
  26. ncbi Polymorphic variations in exon 10 of the luteinizing hormone receptor: functional consequences and associations with breast cancer
    Djura Piersma
    Department of Internal Medicine, Erasmus MC, P O Box 2040, 3000 CA Rotterdam, The Netherlands
    Mol Cell Endocrinol 276:63-70. 2007
    ..In conclusion, although functional changes of the LHR 291Ser candidate allele were observed, no associations with breast cancer were found, while the LHR 312Asn allele can be regarded as a weak breast cancer risk allele...
  27. ncbi Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
    Yixin Wang
    Veridex LLC, a Johnson and Johnson Company, San Diego, CA, USA
    Lancet 365:671-9. 2005
    ....